A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers

Summary

The purpose of this study is to determine what the study drug does to the body, what the body does to the study drug, and if the study drug is safe and well tolerated when given to adult healthy volunteers.

Conditions

• Healthy

Interventions

BIOLOGICAL

PF-05230907

0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose

DRUG

Placebo for PF-05230907

0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose

BIOLOGICAL

PF-05230907

0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose

DRUG

Placebo for PF-05230907

0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose

BIOLOGICAL

PF-05230907

1 micrograms per kilogram of PF-05230907, IV bolus, single dose

DRUG

Placebo for PF-05230907

1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose

BIOLOGICAL

PF-05230907

2 micrograms per kilogram of PF-05230907, IV bolus, single dose

DRUG

Placebo for PF-05230907

2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose

BIOLOGICAL

PF-05230907

3 micrograms per kilogram of PF-05230907, IV bolus, single dose

DRUG

Placebo for PF-05230907

3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose

BIOLOGICAL

PF-05230907

5 micrograms per kilogram of PF-05230907, IV bolus, single dose

DRUG

Placebo for PF-05230907

5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose

Sponsors & Collaborators

• Pfizer

  lead INDUSTRY

Principal Investigators

• Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Eligibility

Min Age

18 Years

Max Age

35 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2013-09-30

Primary Completion

2015-03-31

Completion

2015-03-31

Countries

• Belgium

Study Locations